You really need to stick to posting the facts. The company does not have 1.3 billions shares issued, converted and outstanding. Hence, we dont know exactly how many shares (issued recently) are going to be converted 5/6 months from now.
If management can find non dilutive financing to offset the trial costs; the future share conversion (for many of those shares) wont be necessary.
LOL, try posting something that is actually true. It's not an assumption on my part. It's called DD and maybe you should do some prior to posting silly responses. It was a value given by a biotech website that reviewed the acquisition terms and broke down the cost and value. Also if you had done a shred of reading you would also know that ESS was far from discarded it was tied up in a legal battle. But of course that fact doesn't fit your made up story. Because no one would have a costly long drawn out legal battle over a worthless asset now would they? And since you obviously haven't read up on it, yes AMBS bought out the law suit freeing the asset to move forward.
Once again you can make up any story you want but in the end anyone doing their own research will realize you are only telling a story in hopes the PPS will reach your wishful buy in price target.
You are entitled to your opinion but they don't change the facts.
Here is factual information you pretend doesn't exist. LOL
And look it's written by the guy you asked on Twitter what his rating of AMBS was. You must clearly think he is somewhat knowledgeable or you wouldn't ask his opinion. And since you communicate with this Jason on Twitter certainly you were aware this article existed yet wanted to pretend I made up the .21 per share number.
Trying to be less insulting next time you respond to avoid looking like a fool with an agenda.
By Jason Napodano, CFA. "We get ESS worth approximately $0.21 per share. Amarantus stock is at $0.08 per share. Add in MANF for rare eye diseases and the Amarantus pipeline is looking rather impressive. The company has built a group of assets specifically designed to provide shareholders with at least one major value-creating event every year over the next four years. Each of these potential events could provide significant positive return for shareholders. For this reason we continue to believe that Amarantus stock is a good buy at today’s price. The current market capitalization is roughly $75 million. We think it could be worth $150 to $200 million as some of these value-creating events below are realized."
News 
Market Data 
Discover 
AI
